About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a company based in Milford (United States) founded in 2002. Spring Bank Pharmaceuticals has raised $36.7 million across 10 funding rounds from investors including NIH, HHS and European Union. The company has 84 employees as of February 28, 2022. Spring Bank Pharmaceuticals operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
- Headquarter Milford, United States
- Employees 84 as on 28 Feb, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name F-Star Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$36.7 M (USD)
in 10 rounds
-
Latest Funding Round
Not available
-
Investors
NIH
& 3 more
-
Employee Count
84
as on Feb 28, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Spring Bank Pharmaceuticals
Unlock access to complete
Funding Insights of Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals has successfully raised a total of $36.7M across 10 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Invests in biotech firms developing life-saving drugs and technologies.
|
Locked | Locked | Locked | |
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked |
Investor details for Spring Bank Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Spring Bank Pharmaceuticals
Investment portfolio details for Spring Bank Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Spring Bank Pharmaceuticals
Detailed financials for Spring Bank Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Spring Bank Pharmaceuticals Comparisons
Peer comparison for Spring Bank Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
|
| Locked | Locked | Locked |
Developer of diagnostics and bioinformatics platforms for providers
|
Detailed competitors of Spring Bank Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Spring Bank Pharmaceuticals
Complete news archive for Spring Bank Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals was founded in 2002 and raised its 1st funding round 7 years after it was founded.
Spring Bank Pharmaceuticals is headquartered in Milford, United States.
Spring Bank Pharmaceuticals is a funded company, having raised a total of $36.7M across 10 funding rounds to date.
As of Feb 28, 2022, the latest employee count at Spring Bank Pharmaceuticals is 84.
Spring Bank Pharmaceuticals was founded in 2002 and is based in Milford, United States. Operations center on the pharmaceutical sector, where small molecule nucleic acid hybrid compounds are developed to target proteins and enzymes in disease states. SB 9200 is being advanced for viral diseases, including hepatitis B virus and respiratory syncytial virus, by activating immune response proteins in infected cells.
Spring Bank Pharmaceuticals's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Spring Bank Pharmaceuticals has 4 investors. Key investors include NIH, HHS, European Union, and Turmeric Acquisition Corp.